Effects of angiotensin II receptor blockers on renal handling of uric acid in rats

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 4, 2008, Pages 263-270

  Li, Yan ^a   Sato, Masanobu ^a,b   Yanagisawa, Yuichi ^a   Mamada, Hideaki ^a,b   Fukushi, Akimasa ^a,b   Mikami, Kentaro ^a   Shirasaka, Yoshiyuki ^a,b   Tamai, Ikumi ^a,b  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blockers; Rat; Transporter; Uric acid

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 3; PRATOSARTAN; TELMISARTAN; UNCLASSIFIED DRUG; URIC ACID; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; URATE OXIDASE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; HYPERURICEMIA; HYPERURICOSURIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUBULE EPITHELIUM; LOW DRUG DOSE; MALE; NONHUMAN; RAT; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; ABSORPTION; ANIMAL; KIDNEY; METABOLIC CLEARANCE RATE; METABOLISM; SPRAGUE DAWLEY RAT;

ABSORPTION; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; IMIDAZOLES; KIDNEY; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; URATE OXIDASE; URIC ACID; XANTHINE OXIDASE;

EID: 56149092989     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.263     Document Type: Article

References (26)

1. Verdecchia, P., Schillaci, G., Reboldi, G., Santeusanio, F., Porcellati, C. and Brunetti, P.: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA study. Hypertension, 36: 1072-1078 (2000).
2. Nakagawa, T., Kang, D. H., Feig, D., Sanchez-Lozada, L. G., Srinivas, T. R., Sautin, Y., Ejaz, A. A., Segal, M. and Johnson, R. J.: Unearthing uric acid: An ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int., 69: 1722-1725 (2006).
3. Feig, D. I., Mazzali, M., Kang, D.-H., Nakagawa, T., Price, K., Kannelis, J. and Johnson, R. J.: Serum uric acid: A risk factor and a target for treatment? J. Am. Soc. Nephrol., 17: S69-73 (2006).
4. Kutzing, M. K. and Firestein, B. L.: Altered uric acid levels and disease states. J. Pharmacol. Exp. Ther., 324: 1-7 (2008).
5. Alderman, M., Cohen, H., Madhavan, S. and Kivlighn, S.: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension, 34: 144-150 (1999).
6. Sundstrom, J., Sullivan, L., D'Agostino, R. B., Levy, D., Kannel, W. B. and Vasan, R. S.: Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension, 45: 28-33 (2005).
7. Watanabe, S., Kang, D.-H., Feng, L., Nakagawa, T., Kanellis, J., Lan, H., Mazzali, M. and Richard, J. J.: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertens. Res., 40: 355-360 (2002).
8. Corry, D. B., Eslami, P., Yamamoto, K., Nyby, M. D., Makino, H. and Tuck, M. L.: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular reninangiotensin system. J. Hypertens., 26: 269-75 (2008).
9. Doehner, W., Schoene, N., Rauchhaus, M., Leyva-Leon, F., Pavitt, D. V., Reaveley, D. A., Schuler, G., Coats, A. J., Anker, S. D. and Hambrecht, R.: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation., 105: 2619-24 (2002).
10. Baldus, S., Müllerleile, K., Chumley, P., Steven, D., Rudolph, V., Lund, G. K., Staude, H. J., Stork, A., Köster, R., Kähler, J., Weiss, C., Münzel, T., Meinertz, T., Freeman, B. A. and Heitzer, T.: Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic. Biol. Med., 41: 1282-8 (2006).
11. Siu, Y. P., Leung, K. T. and Tong, M. K. H.: Use of allopurinol in slowing the progression of renal disease through its ability in lowering serum uric acid level. Am. J. Kid. Dis., 47: 51-59 (2006).
12. Manolis, A. J., Grossman, E., Jelakovic, B., Jacovides, A., Bernhardi, D. C., Cabrera, W. J., Watanabe, L. A., Barragan, J., Matadamas, N., Mendiola, A., Woo, K. S., Zhu, J. R., Mejia, A. D., Bunt, T., Dumortier, T. and Smith, R. D.: Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin. Ther., 22: 1186-1203 (2000).
13. Ogihara, T., Saruta T., Shimamoto K., Matsuoka H. and Rakugi H., Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens. Res., 31: 281-287 (2008).
14. Sica, D. and Schoolwerth, A.: Renal handling of organic anions and cations: excretion of uric acid. 6th ed. The Kidney, ed. B. BM. 2000, Philadelphia, PA: Saunders.
15. Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Cha, S. H., Hosoyamada, M., Takeda, M., Sekine, T., Igarashi, T., Matsuo, H., Kikuchi, Y., Oda, T., Ichida, K., Hosoya, T., Shimokata, K., Niwa, T., Kanai, Y. and Endou, H.: Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature, 417: 447-452 (2002).
16. Iwanaga, T., Sato, M., Maeda, T., Ogihara, T. and Tamai, I.: Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J. Pharmacol. Exp. Ther., 320: 211-217 (2007).
17. Sato, M., Iwanaga, T., Mamada, H., Ogihara, T., Yabuuchi, H., Maeda, T. and Tamai, I.: Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm. Res., 25: 639-646 (2008).
18. Hatch, M., Freel, R. W., Shahinfar, S. and Vaziri, N. D.: Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. J. Pharmacol. Exp. Ther., 276: 187-193 (1996).
19. Kahn, A. M. and Weinman, E. J.: Urate transport in the proximal tubule: in vivo and vesicle studies. Am. J. Physiol. Renal. Physiol., 249: F789-798 (1985).
20. Edwards, R. M., Trizna, W., Stack, E. J. and Weinstock, J.: Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J. Pharmacol. Exp. Ther., 276: 125-129 (1996).
21. Sekine, T., Watanabe, N., Hosoyamada, M., Kanai, Y. and Endou, H.: Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem., 272: 18526-18529 (1997).
22. Anzai, N., Kanai, Y. and Endou, H.: New insights into renal transport of urate. Curr. Opin. Rheumatol., 19: 151-157 (2007).
23. Kahn, A. M., Branham, S. and Weinman, E. J.: Mechanism of urate and p-aminohippurate transport in rat renal microvillus membrane vesicles. Am. J. Physiol. Renal. Physiol., 245: F151-158 (1983).
24. Iwanaga, T., Kobayashi, D., Hirayama, M., Maeda, T. and Tamai, I.: Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab. Dispos., 33: 1791-1795 (2005).
25. Burgess, E. D. and Buckley, S.: Acute natriuretic effect of telmisartan in hypertensive patients. Am. J. Hypertens., 13: S183 (2000).
26. Hagos, Y., Bahn, A., Vormfelde, S. V., Brockmoller, J. and Burckhardt, G.: Torasemide Transport by Organic Anion Transporters Contributes to Hyperuricemia. J. Am. Soc. Nephrol., 18: 3101-3109 (2007).